Enzell: Commercial CCPC Designation for Global CAR-T Therapy

Newspim South Korea

Overview

Enzell has been designated as a commercial Centralized Cell Processing Center (CCPC) by a global pharmaceutical company for CAR-T therapy production. The company has also developed a proprietary process that increases CAR-T cell yield by more than four times compared to existing methods.

In Depth

Key Findings

Enzell, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), has been appointed as a commercial Centralized Cell Processing Center (CCPC) by a global pharmaceutical company. This designation expands Enzell’s existing partnership with global firms from clinical-stage cell processing to commercial-scale production for Chimeric Antigen Receptor T-cell (CAR-T) therapies.

Technical Details

Under this arrangement, Enzell processes cells collected from patient blood at its Good Manufacturing Practice (GMP) facilities to supply semi-finished products, which the client then uses to manufacture the final CAR-T therapy. To improve productivity, Enzell has filed a patent for a proprietary process that optimizes T-cell activation conditions and culture environments to reduce cell death and proliferation decline.

• Yield Improvement: Internal comparative tests show that the proprietary process increases final CAR-T cell yield by more than four times compared to existing processes.
• Quality Control: The new process has demonstrated a reduction in cell quality variance between different donors.

Background and Context

Enzell has previously served as a clinical CCPC for multiple global pharmaceutical companies, handling the processing of patient-derived cells and the supply of semi-finished products. The company is a KOSDAQ-listed CGT CDMO that entered the public market in 2024 and maintains various contract manufacturing projects with global partners.

Significance and Outlook

Enzell plans to integrate its proprietary process technology with closed automated manufacturing system verification technology through a national project funded by the Ministry of Trade, Industry and Energy. The company intends to refine these CAR-T production solutions to match specific cell characteristics and development pipelines for various clients, thereby expanding its overall CGT CDMO business footprint.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime